Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    146
    ...
ATC Name B/G Ingredients Dosage Form Price
J01FA09 RITHROCID G Clarithromycin - 500mg 500mg Tablet, film coated 686,704 L.L
L01FA01 RITUXIREL BioTech Rituximab - 100mg/10ml 100mg/10ml Injectable concentrated solution L.L
L01FA01 RITUXIREL BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrated solution L.L
L01FA01 RITUXIREL BioTech Rituximab - 100mg/10ml 100mg/10ml Injectable concentrated solution 11,708,063 L.L
L01FA01 RITUXIREL BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrated solution 45,258,360 L.L
N06DA03 RIVASTIGMINE ARROW G Rivastigmine - 3mg 3mg Capsule 842,589 L.L
N06DA03 RIVASTIGMINE ARROW G Rivastigmine - 3mg 3mg Capsule 842,589 L.L
N06DA03 RIVASTIGMINE ARROW G Rivastigmine - 1.5mg 1.5mg Capsule 684,016 L.L
N06DA03 RIVASTIGMINE ARROW G Rivastigmine - 1.5mg 1.5mg Capsule 684,016 L.L
N06DA03 RIVASTIGMINE ARROW G Rivastigmine - 4.5mg 4.5mg Capsule 842,589 L.L
N06DA03 RIVASTIGMINE ARROW G Rivastigmine - 4.5mg 4.5mg Capsule 842,589 L.L
N03AE01 RIVOTRIL B Clonazepam - 0.5mg 0.5mg Tablet, scored 403,153 L.L
N03AE01 RIVOTRIL B Clonazepam - 2mg 2mg Tablet, scored 503,941 L.L
B01AF01 RIXALTA 10 G Rivaroxaban - 10mg 10mg Tablet, film coated 671,921 L.L
B01AF01 RIXALTA 15 G Rivaroxaban - 15mg 15mg Tablet, film coated 1,164,664 L.L
B01AF01 RIXALTA 20 G Rivaroxaban - 20mg 20mg Tablet, film coated 1,164,664 L.L
L01FA01 RIXATHON BioTech Rituximab - 100mg/10ml 100mg/10ml Injectable concentrate for solution 28,438,096 L.L
L01FA01 RIXATHON BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrate for solution 66,951,899 L.L
L01FA01 RIXATHON BioTech Rituximab - 500mg/50ml 500mg/50ml Injectable concentrate for solution 116,417,745 L.L
N02CC04 RIZATRIPTAN ARROW G Rizatriptan - 10mg 10mg Tablet 1,182,581 L.L
D10AD04 ROACCUTANE B Isotretinoin - 0.05% 0.05% Gel 932,627 L.L
J01DD04 ROCEPHIN IV B Ceftriaxone (sodium) - 1g 1g Injectable lyophilised powder for solution+diluent 757,927 L.L
J01DD04 ROCEPHIN IM B Ceftriaxone (sodium) - 1g 1g Injectable lyophilised powder for solution+diluent 731,050 L.L
J01DD04 ROCICARE G Ceftriaxone - 1g 1g Injectable powder for solution 9,382,061 L.L
M03AC09 ROCUCELL G Rocuronium bromide - 50mg/5ml 50mg/5ml Injectable solution 3,633,494 L.L
M01AB05 ROFENAC D G Diclofenac free acid - 50mg 50mg Tablet, dispersible 408,528 L.L
D05AX52 ROLIP G Calcipotriol - 50mcg, Betamethasone - 0.5mg Ointment 1,574,983 L.L
R03DC03 ROMILAST G Montelukast (sodium) - 5mg 5mg Tablet, mouth dissolving 518,723 L.L
R03DC03 ROMILAST G Montelukast (sodium) - 10mg 10mg Tablet, film coated 228,453 L.L
R03DC03 ROMILAST G Montelukast (sodium) - 4mg 4mg Tablet, mouth dissolving 405,840 L.L
    ...
    146
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025